Scott P. Henry

5.5k total citations
105 papers, 3.8k citations indexed

About

Scott P. Henry is a scholar working on Molecular Biology, Immunology and Genetics. According to data from OpenAlex, Scott P. Henry has authored 105 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 32 papers in Immunology and 14 papers in Genetics. Recurrent topics in Scott P. Henry's work include DNA and Nucleic Acid Chemistry (30 papers), RNA Interference and Gene Delivery (26 papers) and Advanced biosensing and bioanalysis techniques (23 papers). Scott P. Henry is often cited by papers focused on DNA and Nucleic Acid Chemistry (30 papers), RNA Interference and Gene Delivery (26 papers) and Advanced biosensing and bioanalysis techniques (23 papers). Scott P. Henry collaborates with scholars based in United States, Sweden and South Korea. Scott P. Henry's co-authors include Richard S. Geary, Arthur A. Levin, Douglas J. Kornbrust, Rosie Z. Yu, Carol S. Auletta, David Monteith, C. Frank Bennett, Sebastien A. Burel, Lisa R. Grillone and Patricia C. Giclas and has published in prestigious journals such as Nucleic Acids Research, Circulation and Journal of Clinical Oncology.

In The Last Decade

Scott P. Henry

102 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott P. Henry United States 35 2.7k 636 423 312 265 105 3.8k
Neil Ashley United Kingdom 21 1.3k 0.5× 393 0.6× 147 0.3× 403 1.3× 297 1.1× 33 2.3k
Alexander Y. Tsygankov United States 30 2.1k 0.8× 1.0k 1.6× 210 0.5× 172 0.6× 239 0.9× 88 3.6k
Françoise Porteu France 26 1.3k 0.5× 887 1.4× 268 0.6× 118 0.4× 272 1.0× 51 2.6k
Niels Bovenschen Netherlands 29 945 0.4× 1.1k 1.7× 292 0.7× 148 0.5× 247 0.9× 83 2.7k
Jean‐Max Pasquet France 32 1.5k 0.6× 685 1.1× 444 1.0× 126 0.4× 402 1.5× 69 3.3k
John F. Lyons United States 32 2.7k 1.0× 347 0.5× 321 0.8× 308 1.0× 551 2.1× 81 4.3k
Richard Piekarz United States 36 3.6k 1.3× 736 1.2× 202 0.5× 222 0.7× 232 0.9× 137 5.3k
Joseph R. Slupsky United Kingdom 29 1.5k 0.6× 1.3k 2.1× 587 1.4× 199 0.6× 321 1.2× 61 4.2k
John R. Mills United States 30 1.8k 0.7× 259 0.4× 201 0.5× 193 0.6× 176 0.7× 110 3.1k
Kazuo Todokoro Japan 38 2.4k 0.9× 846 1.3× 427 1.0× 296 0.9× 330 1.2× 74 4.2k

Countries citing papers authored by Scott P. Henry

Since Specialization
Citations

This map shows the geographic impact of Scott P. Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott P. Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott P. Henry more than expected).

Fields of papers citing papers by Scott P. Henry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott P. Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott P. Henry. The network helps show where Scott P. Henry may publish in the future.

Co-authorship network of co-authors of Scott P. Henry

This figure shows the co-authorship network connecting the top 25 collaborators of Scott P. Henry. A scholar is included among the top collaborators of Scott P. Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott P. Henry. Scott P. Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McCaleb, Michael L., Steven G. Hughes, Tamar R. Grossman, et al.. (2025). Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 230(2). 152876–152876. 2 indexed citations
2.
Mazur, Curt, Oleksandr Platoshyn, Sebastien A. Burel, et al.. (2025). Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system. Nucleic Acids Research. 54(3).
3.
Johansson, Karl, Johan Rebetz, Geneviève Marcoux, et al.. (2024). CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways. Journal of Thrombosis and Haemostasis. 22(11). 3266–3276. 1 indexed citations
4.
Jeong, Ji‐Seong, Tae‐Won Kim, Scott P. Henry, et al.. (2024). A Combined Fertility and Developmental Toxicity Study with an Antisense Oligonucleotide Targeting Murine Apolipoprotein C-III mRNA in Mice. Nucleic Acid Therapeutics. 34(6). 285–294.
5.
Shen, Lijiang, Andrea Li Ann Wong, Satoru Oneda, et al.. (2023). Complement C3d/C4d Deposition on Platelets Correlates with 2′-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys. Nucleic Acid Therapeutics. 33(3). 209–225. 3 indexed citations
6.
Lamb, Martin, et al.. (2022). Antisense Oligonucleotide-Related Macrovesicular Vacuolation of Hippocampal Neurons in Nonhuman Primates. Toxicologic Pathology. 50(2). 197–210. 4 indexed citations
7.
Burel, Sebastien A., Todd Machemer, Brenda F. Baker, et al.. (2022). Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. Nucleic Acid Therapeutics. 32(6). 457–472. 14 indexed citations
8.
Machemer, Todd, et al.. (2022). Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab Cells. Nucleic Acid Therapeutics. 32(6). 473–485. 12 indexed citations
9.
Henry, Scott P., Cecilia Arfvidsson, David Crowe, et al.. (2022). Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs. Nucleic Acid Therapeutics. 32(5). 369–377. 8 indexed citations
10.
11.
Curtis, Brian R., Lijiang Shen, Eugene Schneider, et al.. (2020). Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. Nucleic Acid Therapeutics. 30(2). 94–103. 26 indexed citations
12.
Kim, Tae‐Won, et al.. (2019). Impurity Qualification Toxicology Study for a 2′-O-Methoxyethyl-Modified Antisense Inhibitor in Mice. Nucleic Acid Therapeutics. 30(1). 14–21. 1 indexed citations
13.
Zanardi, Thomas A., et al.. (2018). Chronic Toxicity Assessment of 2′- O -Methoxyethyl Antisense Oligonucleotides in Mice. Nucleic Acid Therapeutics. 28(4). 233–241. 16 indexed citations
14.
McCaleb, Michael L., Tamar R. Grossman, Peter Adamson, et al.. (2017). Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies. Investigative Ophthalmology & Visual Science. 58(8). 1952–1952. 5 indexed citations
15.
16.
Shemesh, Colby S., Rosie Z. Yu, Mark S. Warren, et al.. (2017). Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs. Molecular Therapy — Nucleic Acids. 9. 34–47. 27 indexed citations
17.
Shen, Lijiang, Gene Hung, Rie Kikkawa, et al.. (2016). Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2′- O -Methoxyethyl Modified Antisense Oligonucleotide. Nucleic Acid Therapeutics. 26(4). 236–249. 18 indexed citations
18.
Shen, Lijiang, Ashley Frazer‐Abel, Paul R. Reynolds, et al.. (2014). Mechanistic Understanding for the Greater Sensitivity of Monkeys to Antisense Oligonucleotide–Mediated Complement Activation Compared with Humans. Journal of Pharmacology and Experimental Therapeutics. 351(3). 709–717. 34 indexed citations
19.
20.
Henry, Scott P. & S. Derek Killilea. (1994). Purification and Characterization of Bovine Heart Glycogen Synthase Kinase-3. Preparative Biochemistry. 24(3-4). 263–277. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neil Ashley Breakdown of academic impact, for papers by Alexander Y. Tsygankov Breakdown of academic impact, for papers by Françoise Porteu Breakdown of academic impact, for papers by Niels Bovenschen Breakdown of academic impact, for papers by Jean‐Max Pasquet Breakdown of academic impact, for papers by John F. Lyons Breakdown of academic impact, for papers by Richard Piekarz Breakdown of academic impact, for papers by Joseph R. Slupsky Breakdown of academic impact, for papers by John R. Mills Breakdown of academic impact, for papers by Kazuo Todokoro
Rankless by CCL
2026